0001342219 false 2019 FY 0001342219 2019-01-01 2019-12-31 0001342219 2019-12-31 0001342219 2019-06-30 0001342219 2018-12-31 0001342219 2018-01-01 2018-12-31 0001342219 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001342219 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001342219 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001342219 2017-12-31 0001342219 us-gaap:CommonStockMember 2017-12-31 0001342219 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001342219 us-gaap:RetainedEarningsMember 2017-12-31 0001342219 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001342219 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001342219 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001342219 us-gaap:CommonStockMember 2018-12-31 0001342219 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001342219 us-gaap:RetainedEarningsMember 2018-12-31 0001342219 us-gaap:CommonStockMember 2019-12-31 0001342219 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001342219 us-gaap:RetainedEarningsMember 2019-12-31 0001342219 fil:GemwoodProductionsIncMember 2019-01-01 2019-12-31 0001342219 fil:KreidoLabsMember 2019-01-01 2019-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

(Mark One)

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For Fiscal Year Ended:  December 31, 2019

OR

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission file number:  000-55909

KREIDO BIOFUELS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada

 

20-3240178

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)

 

 

 

Unit 1010-15, 10/F, Tower B,

New Mandarin Plaza,

14 Science Museum Road,

Tsim Sha Tsui East, KLN, HK

 

(Address of principal executive offices) (Zip Code)

 

 

 

 

 

+852 9862 6962

 

 

(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Act:  None

Securities registered under Section 12(g) of the Act:  Common Stock, par value $0.001

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes [  ]   No [X] 

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes [] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [ X ]   No []

Indicate by checkmark whether the registrant has submitted electronically on its corporate Website, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [  ] Yes [X] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   :

Large Accelerated Filer [  ]Accelerated Filer [  ] 

Non-Accelerated Filer [  ]Smaller reporting company ☒ 

Emerging growth company ☒ 


1



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☒    No ☐  

As of December 31, 2019, the Company had outstanding 1,956,452 shares of common stock, par value $0.001 per share.  Of those, 1,187,209 shares were held by non-affiliates of the registrant.  As of June 30, 2019, the aggregate market value of the registrant’s voting common stock held by non-affiliates was approximately $4,143,359 based on the closing price of the Company’s common stock as quoted on the OTC Markets on that date.

DOCUMENTS INCORPORATED BY REFERENCE

 

If the following documents are incorporated by reference, briefly describe them and identify the part of the Form 10-K (e.g., Part I, Part II, etc.) into which the document is incorporated:  (1) any annual report to security holders; (2) any proxy or information statement; and (3) any prospectus filed pursuant to Rule 424(b) or (c) of the Securities Act of 1933, as amended (“Securities Act”).


Not Applicable.  


2



TABLE OF CONTENTS

 

Item Number and Caption

Page

Item 1.

Description Of Business

2

Item 1A.

Risk Factors

4

Item 1B.

Unresolved Staff Comments

4

Item 2.

Properties

6

Item 3.

Legal Proceedings

4

Item 4.

Mine Safety Disclosures

4

Part II

 

4

Item 5.

Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities

4

Item 6.

Selected Financial Data

5

Item 7.

Management’s Discussion And Analysis Of Financial Condition And Results Of Operations

6

Item 8   

Financial Statements And Supplementary Data

 

Item 9.

Changes In And Disagreements With Accountants On Accounting And Financial Disclosure

20

Item 9B.

Other Information

17

Part III

 

17

Item 10.

Directors, Executive Officers, And Corporate Governance

17

Item 11.

Executive Compensation

19

Item 12.

Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters

20

Item 13.

Certain Relationships And Related Transactions, And Director Independence

20

Item 14.

Principal Accountant Fees And Services

21

Part IV

 

21

Item 15.

Exhibits And Financial Statement Schedules

21

Signatures

 

22


1



ITEM 1DESCRIPTION OF BUSINESS 

 

Business Development

 

When used in this Form 10-K, the words "expects," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements speak only as of the date hereof.  Kreido Biofuels expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based. This discussion should be read together with the financial statements and other financial information included in this Form 10-K. Readers should carefully review the other documents the Company files with  the Securities and Exchange Commission, including the Quarterly Reports on Form 10-Q, the Annual Report on Form 10-K and any Current Reports on Form 8-K filed by the Company.

 

Background

 

Kreido Biofuels, Inc. (“Kreido Biofuels,” “we” or the “Company”) was incorporated on February 7, 2005, under the name Gemwood Productions, for the purpose of marketing and selling day spa services to tourists at resort destinations throughout Mexico. On November 2, 2006, we changed our name to Kreido Biofuels, Inc. in connection with the acquisition of Kreido Laboratories, Inc., a California corporation, and the disposition of the Gemwood Leasco, Inc. subsidiary,  through which entity the tourist business had been carried out. Kreido Laboratories was founded to develop proprietary technology for building micro-composite materials for electronic applications, and developed technology to improve the speed, completeness and efficiency of certain chemical reactions, including esterifications and transesterifications, in the pharmaceutical and special chemical industries.  In the first quarter of 2006, Kreido Labs elected to focus exclusively on the biodiesel industry. This business was not successful, and we sold the technology and related assets to an unrelated party on March 5, 2009. After that disposition, we sought unsuccessfully for another acquisition until the present time. In November of 2018, the Company discontinued operations of its subsidiary, Kreido Labs, Inc.

 

Our registration statement on Form SB-2, file number 333-140718, became effective on June 28, 2007.  Subsequent to the filing of our Annual Report on Form 10-K for the year ended December 31, 2008, we continued to file annual and quarterly reports with the Securities and Exchange Commission on a voluntary basis through the quarter ended September 30, 2009.  On February 16, 2009, we elected to terminate our registration and our election to file periodic reports.  On March 2, 2019, we filed a Form 10 and the registration became effective on May 1, 2019.

 

Our current business will be to seek to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target.    

 

Our acquisition strategy will be to assess a broad range of potential business combination targets and complete a business combination.   In doing so, we will evaluate the historical financial statements of the target, its management, and projected future results. In evaluating a prospective target business, we expect to conduct a thorough due diligence review that will encompass, among other things, meetings with incumbent management and employees, document reviews, inspection of facilities, as well as a review of financial and other information that will be made available to us.

 

We are not prohibited from pursuing a business combination with a company that is affiliated with our management, but we have no plans to do so. We do not plan to retain a significant equity position after closing of any acquisition and management does not plan to continue as part of the new management team.

 

We have not selected any specific business combination target. Our sole officer and director presently has, and in the future may have additional fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity. Accordingly, if our officer and director becomes aware of a business combination opportunity which is suitable for an entity to which he has then-current fiduciary or contractual obligations, he will honor his or her fiduciary or contractual obligations to present such opportunity to such entity. We do not believe, however, that the fiduciary duties or contractual obligations of our officer/director will materially affect our ability to complete our business combination.

 

Our executive officer is not required to commit any specified amount of time to our affairs, and, accordingly, will have conflicts of interest in allocating management time among various business activities, including identifying potential business combination targets and monitoring the related due diligence.

 

Our executive officer may participate in the formation of, or become an officer or director of, any other blank check or shell company with a class of securities registered under the Exchange Act, but in that event, all opportunities will be presented to the Company first.

 

Our Business


2



We are a company incorporated as a Nevada corporation  and with the business purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We intend to effectuate our business combination using only our capital stock, debt or a combination of stock and debt.

 

The issuance of additional shares of our stock in a business combination:

 

•         may significantly dilute the equity interest of investors;

 

•         may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock;

 

•         could cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;

 

•         may have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person seeking to obtain control of us; and

 

•         may adversely affect prevailing market prices for our common stock.

 

Similarly, if we issue debt securities, it could result in:

 

•         default and foreclosure on our assets if our operating revenues after a business combination are insufficient to repay our debt obligations;

 

•         acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

 

•         our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;

 

•        our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;

 

•         our inability to pay dividends on our common stock;

 

•        using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;

 

•         limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;

 

•         increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and

 

•         limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

 

As indicated in the accompanying financial statements, at December 31, 2019, we had $0 in cash. Further, we expect to incur significant costs in the pursuit of our acquisition plans, which could be funded by advances from management. We cannot assure you that our plans to raise capital or to complete our business combination will be successful.

 

Principal Products

 

The Company originally intended to engage in the business of biodiesel.  These plans did not materialize, and the Company is currently considering alternative business opportunities.

 

Future Operating Plan


3



We continue to seek acquisition opportunities for the Company. We hope to acquire operating companies based in China, Hong Kong, or other Asian or Southeast Asian countries. Prospective candidates may be affiliated with current management or significant shareholders.

 

Our acquisition strategy will be to assess a broad range of potential business combination targets and complete a business combination.  In doing so, we will evaluate the historical financial statements of the target, its management, and projected future results.  In evaluating a prospective target business, we expect to conduct a thorough due diligence review that will encompass, among other things, meetings with incumbent management and employees, document reviews, inspection of facilities, as well as a review of financial and other information that will be made available to us.

 

Our sole officer and director presently has, and in the future may have additional, fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity. Accordingly, if our officer and director becomes aware of a business combination opportunity which is suitable for an entity to which he has then-current fiduciary or contractual obligations, he will honor his or her fiduciary or contractual obligations to present such opportunity to such entity. We do not believe, however, that the fiduciary duties or contractual obligations of our officer/director will materially affect our ability to complete a business combination.

 

Our executive officer is not required to commit any specified amount of time to our affairs, and, accordingly, will have conflicts of interest in allocating management time among various business activities, including identifying potential business combination targets and monitoring the related due diligence.

 

Our executive officer may participate in the formation of, or become an officer or director of, any other blank check company with a class of securities registered under the Exchange Act.

 

Reports to Security Holders

 

We are filing this Report with the Securities and Exchange Commission (“SEC”) and will file reports, including quarterly and annual reports, with the Commission pursuant to Section 12(b) or (g) of the Exchange Act. These reports and any other materials filed with the SEC may be read and copied at the SEC's Public Reference Room at 100 F Street NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. We file our reports electronically with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov.

 

ITEM 1ARISK FACTORS 

 

Not applicable.

 

ITEM 1BUNRESOLVED STAFF COMMENTS 

 

Not applicable.

 

 

ITEM 2PROPERTIES 

 

We use a minimal amount of office space provided by our officer. We expect that we will not need dedicated office space until such time as we obtain revenues.

 

 

ITEM 3LEGAL PROCEEDINGS 

 

As of the date of this Report, there is no litigation pending or threatened by or against us. However, from time to time we may be subject to legal proceedings and claims in the ordinary course of business. Such claims, even if not meritorious, would result in the expenditure by us of significant financial and managerial resources.

 

ITEM 4MINE SAFETY DISCLOSURES 

 

Not applicable.

 

PART II

 

ITEM 5MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 


4



Market Information

 

Our common stock is quoted on the OTCQB under the symbol “KRBF”. Trading in our common stock on the OTCQB has been limited and sporadic and the quotations set forth below are not necessarily indicative of actual market conditions. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily reflect actual transactions. Set forth below is the range of high and low bid information for each quarter within the last two fiscal years as provided by the OTC Markets website:

 

Quarter

High

Low

2019 Fourth Quarter

$2.24

$0.74

2019 Third Quarter

$5.50

$1.21

2019 Second Quarter

$6.35

$1.66

2019 First Quarter

$2.99

$1.50

2018 Fourth Quarter

$3.74

$1.40

2018 Third Quarter

$9.00

$3.00

2018 Second Quarter

$7.50

$0.40

2018 First Quarter

$0.80

$0.11

 

Holders

 

As of December 31, 2019, we had approximately 113 shareholders of record of our common stock.

 

Dividends

 

We have not paid any cash dividends to our shareholders since our inception on February 7, 2005. Future payment of dividends is within the discretion of our board of directors and will depend on our earnings, capital requirements, financial condition and other relevant factors. There are no material restrictions limiting, or that are likely to limit, our ability to pay cash dividends on our common stock. We have no present intention to pay cash dividends on our common stock.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

As of the date of this Report, we do not have a compensation plan under which equity securities are authorized for issuance.

 

Recent Sales of Unregistered Securities

 

None

 

Stock Repurchase

 

As of the date of this Report, we do not have a stock repurchase plan.

 

ITEM 6SELECTED FINANCIAL DATA 

 

Not applicable.


5



ITEM 7MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 

 

Background and Overview

 

Kreido Biofuels, Inc. (“Kreido Biofuels,” “we” or the “Company”) was incorporated on February 7, 200,5 under the name Gemwood Productions, for the purpose of marketing and selling day spa services to tourists at resort destinations throughout Mexico. On November 2, 2006, we changed our name to Kreido Biofuels, Inc. in connection with the acquisition of Kreido Laboratories, Inc., a California corporation, and the disposition of the Gemwood Leasco, Inc. subsidiary, through which entity the tourist business had been carried out. Kreido Laboratories was founded to develop proprietary technology for building micro-composite materials for electronic applications, and developed technology to improve the speed, completeness and efficiency of certain chemical reactions, including esterifications and transesterifications, in the pharmaceutical and special chemical industries. In the first quarter of 2006, Kreido Labs elected to focus exclusively on the biodiesel industry. This business was not successful, and we sold the technology and related assets to an unrelated party on March 5, 2009. After that disposition, we sought unsuccessfully for another acquisition until the present time. In November of 2018, the Company discontinued operations of its subsidiary, Kreido Labs, Inc.

 

Our initial registration statement on Form SB-2, became effective on June 28, 2007. Subsequent to the filing of our Annual Report on Form 10-K for the year ended December 31, 2008, we continued to file annual and quarterly reports with the Securities and Exchange Commission on a voluntary basis through the quarter ended September 30, 2009.

 

In November 2018, our former majority shareholder and sole officer G. Reed Petersen approached the then sole officer and director offering to pay off the debt of the Company. Mr. Petersen paid the sum of $171,509 in consideration of 142,924,167 shares of stock of the Company. On March 2, 2019, the Company filed a registration statement on Form 10 with the Securities and Exchange Commission. The registration statement on Form 10 became effective May 1, 2019.

 

On June 5, 2018, the Company and its sole officer and director, G. Reed Petersen, entered into that certain Stock Purchase Agreement (the “Stock Purchase Agreement”), pursuant to which Mr. Petersen agreed to sell to certain purchasers an aggregate of 142,924,167 shares of common stock of the Company (the “Control Shares”), representing approximately 73% of the issued and outstanding stock of the Company, for aggregate cash consideration of $420,000 in accordance with the terms and conditions of the Stock Purchase Agreement. The Stock Purchase Agreement was included as Exhibit 10.1 to that Amendment No. 1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 6, 2018.

 

The sale of the Control Shares consummated on June 29, 2018. As a result, the purchasers hold a controlling interest in the Company and may unilaterally determine the election of the Board and other substantive matters requiring approval of the Company’s stockholders.

 

In connection with the sale of the Control Shares, G. Reed Petersen resigned from his positions as the sole executive officer and director of the Company, effective June 29, 2018. Mr. Petersen’s departure was not due to any dispute or disagreement with the Company on any matter related to the Company’s operations, policies or practices.  Concurrently, the Board of Directors appointed Wai Lim Wong to fill the vacancies created by Mr. Petersen’s resignation, and to serve as the Company’s sole Director, Chief Executive Officer, Chief Financial Officer and Secretary.

 

 

Results of Operations

 

Following is management’s discussion of the relevant items affecting results of operations for the years ended 2019 and 2018.

 

Revenues. The Company generated revenues of $-0- during the year ended December 31, 2019 as compared to $-0- for the year ended December 31, 2018.

 

Operating Expenses.  Operating expenses for the year ended December 31, 2019 were $33,336, consisting primarily of professional fees, compared to $38,958 for the year ended December 31, 2018.  The decrease is mainly the result of a decrease in legal and professional expenses.

 

Operating expenses consisted of professional fees and general and administrative fees. The increase in operating expenses resulted from increased professional and general and administrative fees arising from the sale of the Control Shares. The filing of the


6



Company’s Form 10 also added to the increased professional fees. We expect operating expenses to increase as we continue our process of identifying prospective acquisition targets and hopefully successfully consummate such an acquisition.

 

Other Income (Expense). The Company had net other income of $ -0- for the year ended December 31, 2019 compared to $ 7,416 during the year ended December 31, 2018.

 

Net Loss.  For the year ended December 31, 2019, the Company had a net loss of $33,336, as compared to $38,958 for the year ended December 31, 2018. The increase in net loss was due to the increase in professional fees and general and administrative fees incurred by the Company.

 

Liquidity and Capital Resources

 

As of December 31, 2019, our primary source of liquidity consisted of $-0- in cash and cash equivalents. Since inception, we have financed our operations through a combination of short and long-term loans, and through the private placement of our common stock.

 

Going Concern Uncertainties.

 

We have sustained significant net losses which have resulted in a total stockholders’ deficit at December 31, 2019 of ($57,794) and are currently experiencing a substantial shortfall in operating capital which raises doubt about our ability to continue as a going concern. Until we successfully consummate an acquisition with an operating company, we expect to continue to incur net losses. Depending upon the financial profile of our acquired company, we may continue in our net loss position even after the acquisition of an operating company. With the expected cash requirements for the coming months, without additional cash inflows from an increase in revenues combined with continued cost-cutting or a receipt of cash from capital investment, there is substantial doubt as to the Company’s ability to continue operations.

 

There is presently no agreement in place with any source of financing for the Company, and we cannot be assured that the Company will be able to raise any additional funds, or that such funds will be available on acceptable terms. Funds raised through future equity financing will likely be substantially dilutive to current shareholders. Lack of additional funds will materially affect the Company and its business and may cause us to cease operations. Consequently, shareholders could incur a loss of their entire investment in the Company.

 

Net Cash Used in Operating Activities.

 

For the year ended December 31, 2019, net cash used in operating activities was $0, which consisted primarily of a net loss of $33,336, and increase in account payable of $13,057, and an increase in related party payables of $20,279.

 

For the year ended December 31, 2018, net cash used in operating activities was $9,427, which consisted primarily of a net loss of $38,958, and increase in account payable of $11,325, an increase in related party payables of $12,233, an increase in notes payable - short term of $3,973 and an increase in prepaid expenses of $2,000.

 

Net Cash Used In/Provided By Investing Activities.

 

There was no net cash used in or provided by investing activities during the year ended December 31, 2019, and 2018.

 

Net Cash Provided By Financing Activities.

 

For the year ended December 31, 2019, net cash provided by financing activities was 0.

 

For the year ended December 31, 2018, net cash provided by financing activities was $9,427, consisting primarily of proceeds of $21,350 from a related party, offset by repayments of $11,923 on an outstanding note payable.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.  


7



Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

Critical accounting policies

 

The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments which are based on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of their evaluation form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions and circumstances. Our significant accounting policies are more fully discussed in Note 2 to our financial statements contained herein.  

 

Recent accounting pronouncements

 

The recent accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our unaudited condensed consolidated financial statements upon adoption.


8


PICTURE  


Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Kreido Biofuels Inc

 

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Kreido Biofuels Inc (the "Company") as of December 31, 2019, the related consolidated statements of operations, changes in shareholders' equity and cash flows, for the year ended December 31, 2019, and the related notes collectively referred to as the "financial statements. The financial statement of Kreido Biofuels Inc. As of December 31, 2018, were audited by other auditors whose report dated April 15, 2019, expressed an unqualify opinion on those statement.

 

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019, and the results of its operations and its cash flows for the year ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.

 

Going Concern

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has continuously incurred a net loss of $33,336 for the year ended December 31, 2019, and an accumulated deficit of $49,044,627 at December 31, 2019. The continuation of the Company as a going concern through December 31, 2019, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide the additional cash to meet the Company’s obligations as they become due.

 

These factors raise substantial doubt about the company ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of the uncertainty.

 

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion

 

 

OLAYINKA OYEBOLA & CO.

(Chartered Accountants)

 

We have served as the Company's auditor since September 2020.

September 24th, 2021.

 

Lagos Nigeria


9



ITEM 8FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

 

Kreido Biofuels, Inc.

Consolidated Balance Sheets

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

December 31,

 

 

 

2019

 

2018

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

$

                     -

 

$

                      -

 

Due from Related Party

 

                     -

 

 

                      -

 

Prepaid Expenses

 

                     -

 

 

                      -

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

                     -

 

 

                      -

 

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

                     -

 

 

                      -

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts Payable

 

             25,282

 

 

             12,225

 

Related Party Payable

 

             32,512

 

 

             12,233

 

Note Payable - Short Term

 

                     -

 

 

                      -

 

 

 

 

 

 

 

 

 

 

 

Total Current Liabilities

 

             57,794

 

 

             24,458

 

 

 

 

 

 

 

 

 

LONG TERM LIABILITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Note Payable - Long Term

 

                     -

 

 

                      -

 

 

 

 

 

                     -

 

 

                      -

 

 

Total Long Term Liabilities

 

                     -

 

 

                      -

 

 

 

 

 

 

 

 

 

 

 

 

Total Liabilities

$

             57,794

 

$

             24,458

 

 

 

 

 

 

 

 

 

STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock; 10,000,000 shares authorized,
at $0.001 par value, 0 shares issued and outstanding

 

                     -

 

 

                      -

 

 

 

 

 

 

 

 

Common stock; 300,000,000 shares authorized,
at $0.001 par value, 1,956,452
shares issued and outstanding

 

               1,956

 

 

            195,645

 

Additional paid-in capital

 

       48,984,877

 

 

       48,791,188

 

Accumulated Deficit

 

      (49,044,627)

 

 

      (49,011,291)

 

 

 

 

 

 

 

 

 

 

 

Total Stockholders' Deficit

 

            (57,794)

 

 

            (24,458)

 

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$

                     -

 

$

                      -

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these financial statements.


10



 

Kreido Biofuels, Inc.

Consolidated Statements of Operations

 

 

 

 

For the Years Ended

 

 

 

December 31,

 

 

2019

 

2018

 

 

 

 

 

 

 

 

REVENUES

$

                 -

 

$

                     -

 

 

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

 

Professional Fees

 

         28,609

 

 

            34,342

 

General and administrative

 

           4,727

 

 

              4,616

 

 

Total operating expenses

 

         33,336

 

 

            38,958

 

 

 

 

 

 

 

 

OTHER INCOME/EXPENSE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on settlement of debt

 

                 -

 

 

                     -

 

 

 

 

 

 

 

 

 

 

Total other income/(expense)

 

                 -

 

 

                     -

 

 

 

 

 

 

 

 

 

 

Total Expenses

 

         33,336

 

 

            38,958

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

        (33,336)

 

 

           (38,958)

 

 

 

 

 

 

 

 

OTHER EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain from discontinued operations

 

-

 

 

                     -

 

 

 

 

 

 

 

 

 

 

Total Other Expenses

 

                 -

 

 

                     -

 

 

 

 

 

 

 

 

LOSS BEFORE INCOME TAXES

 

        (33,336)

 

 

           (38,958)

 

 

 

 

 

 

 

 

PROVISION FOR INCOME TAXES

 

                 -

 

 

                     -

 

 

 

 

 

 

 

 

NET LOSS

$

        (33,336)

 

$

           (38,958)

 

 

 

 

 

 

 

 

BASIC AND DILUTED LOSS PER SHARE

$

           (0.02)

 

$

              (0.02)

 

 

 

 

 

 

 

 

BASIC AND DILUTED WEIGHTED AVERAGE  
NUMBER OF COMMON SHARES
OUTSTANDING

 

     1,956,452

 

 

        1,956,452

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these financial statements


11



Kreido Biofuels, Inc.

Consolidated Statement of Stockholder's Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

Additional

 

 

 

Stockholders'

 

 

Common Stock

 

Paid-In

 

Accumulated

 

Equity

 

Shares

 

Amount

 

Capital

 

Deficit

 

(Deficit)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2017

$

      1,956,452

 

$

     1,956

 

$

  48,963,527

 

$

  (48,972,333)

 

$

      (6,850)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on forgiveness of debt

 

                   -

 

 

            -

 

 

        21,350

 

 

                  -

 

 

      21,350

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss for the year December 31, 2018

 

                   -

 

 

            -

 

 

                 -

 

 

        (38,958)

 

 

    (38,958)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2018

$

      1,956,452

 

$

     1,956

 

$

  48,984,877

 

$

  (49,011,291)

 

$

    (24,458)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss for the year December 31, 2019

 

                   -

 

 

            -

 

 

                 -

 

 

        (33,336)

 

 

    (33,336)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2019

$

      1,956,452

 

$

     1,956

 

$

  48,984,877

 

$

  (49,044,627)

 

$

    (57,794)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these financial statements.


12


 


Kreido Biofuels, Inc.

Consolidated Statements of Cash Flows

 

 

 

 

 

 

For the Years Ended

 

 

 

 

 

December 31,

 

 

 

 

2019

 

2018

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

     (33,336)

 

$

     (38,958)

 

Adjustments to reconcile net loss to net cash
used in operating activities:

 

 

 

 

 

 

 

Services contributed by shareholders

 

               -

 

 

               -

 

 

Expenses paid on behalf of company

 

               -

 

 

               -

 

 

Gain on discontinued operations

 

               -

 

 

               -

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Change in prepaid expenses

 

               -

 

 

         2,000

 

 

Change in notes payable - Short term

 

               -

 

 

         3,973

 

 

Change in accounts payable related party

 

       20,279

 

 

       12,233

 

 

Change in accounts payable

 

       13,057

 

 

       11,325

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Cash Used in
Operating Activities

 

               -

 

 

       (9,427)

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

               -

 

 

               -

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

Repayments on note payable

 

               -

 

 

     (11,923)

 

 

Proceeds from related party

 

               -

 

 

       21,350

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Cash Provided by
Financing Activities

 

               -

 

 

         9,427

 

 

 

 

 

 

 

 

 

 

 

 

NET INCREASE IN CASH

 

               -

  

  

               -

 

 

 

 

 

 

 

 

 

 

 

 

CASH AT BEGINNING OF PERIOD

 

               -

 

  

               -

 

 

 

 

 

 

 

 

 

 

 

 

CASH AT END OF PERIOD

$

               -

 

$

               -

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF
CASH FLOW INFORMATION
CASH PAID FOR:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest

$

               -

 

$

               -

 

 

Income Taxes

$

               -

 

$

               -

 

 

 

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock issued for debt

 

               -

 

 

               -

 

 

Conversion of accounts payable to note payable

 

               -

 

 

               -

 

 

Stock issued for accounts payable - related party

               -

 

 

               -

 

The accompanying notes are an integral part of these financial statements.


13


KREIDO BIOFUELS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018


NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

 

Nature of Business

Kreido Biofuels, Inc. was incorporated as Gemwood Productions, Inc. under the laws of the State of Nevada on February 7, 2005. Gemwood Productions, Inc. changed its name to Kreido Biofuels, Inc. on November 2, 2006. The Company took its current form on January 12, 2007 when Kreido Laboratories (“Kreido Labs”), completed a reverse triangular merger with Kreido Biofuels, Inc.

 

Kreido Labs, formerly known as Holl Technologies Company, was incorporated on January 13, 1995 under the laws of the State of California. Since incorporation, Kreido Labs has been engaged in activities required to develop, patent and commercialize its products. Kreido Labs was the creator of reactor technology that was designed to enhance the manufacturing of a broad range of chemical products.

 

The cornerstone of Kreido Labs’ technology was its patented STT® (Spinning Tube in Tube) diffusional chemical reacting system, which were both a licensable process and a licensable system. In 2005, the Company demonstrated how the STT® could make biodiesel from vegetable oil rapidly with almost complete conversion and less undesirable by-products. The Company had continued to pursue this activity, built and tested a pilot biodiesel production unit and, prior to June 20, 2008, was in the process of developing the first of its commercial biodiesel production plants in the United States that, if constructed and put into operation, was expected to produce approximately 33 million to 50 million gallons per year. On June 20, 2008, the Company announced that due to the weakening of the economy, the continued financial market turmoil and the inability to raise needed capital to finance site construction and plant start-up costs, the Company was suspending work regarding its flagship biodiesel production plant at the Port of Wilmington, North Carolina. In November of 2018, the Company discontinued operations of its subsidiary, Kreido Labs, Inc.

 

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

 

Principles of Consolidation

The accompanying consolidated financial statements for the years ended December 31, 2019 and 2018 include the accounts of the Company and its wholly-owned subsidiary, Kreido Laboratories, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Accounting Estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

Financial instruments, including cash and accrued expenses and other liabilities are carried at amounts, which reasonably approximate their fair value due to the short-term nature of these amounts or due to variable rates of interest, which are consistent with market rates.

 

Loss per Common Share

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by

 

 


14


KREIDO BIOFUELS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018


 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year.

 

Cash and Cash Equivalents

The Company considers all highly liquid investment with an original maturity of three months or less to be cash equivalents.  At December 31, 2019 and 2018, cash and cash equivalents include cash on hand and cash in the bank.

 

Stock-based compensation

The Company recognizes compensation expense for all stock-based compensation awards based on the grant-date fair value estimated in accordance with the provisions of ASC 718.

 

Income Taxes

Under ASC 740, “Income Taxes,” deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2019 there were no deferred taxes as there was a full valuation allowance due to the uncertainty of the realization of net operating loss carry forward prior to expiration.

 

Fair Value of Financial Instruments 

The Company follows guidance for accounting for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements on a recurring basis. Additionally, the Company adopted guidance for fair value measurement related to nonfinancial items that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

 

Level 2 inputs are inputs other than quoted prices included within Level 1that are observable for the asset or liability, either directly or indirectly.

 

Level 3 inputs are unobservable inputs for the asset or liability. The carrying amounts of financial assets such as cash approximate their fair values because of the short maturity of these instruments.

 

Recent Accounting Pronouncements

The FASB established the Accounting Standards Codification (“Codification” or “ASC”) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”).

 

 

 

 

 

 

 

 


15


KREIDO BIOFUELS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018


 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Rules and interpretative releases of the Securities and Exchange Commission (“SEC”) issued under authority of federal securities laws are also sources of GAAP for SEC registrants.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

NOTE 3 - GOING CONCERN

 

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from management sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However, Management cannot provide any assurances that the Company will be successful in accomplishing any of its plans, which raises substantial doubt about the ability of the Company to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

NOTE 4 – STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company’s Articles of Incorporation authorize the issuance of up to 300,000,000 common shares, par value $0.001 per share, and 10,000,000 preferred shares, also $0.001 par value. There were 1,956,452 shares of common stock outstanding at December 31, 2019 and 2018, respectively. There were no preferred shares outstanding during any periods presented.   

 

2018

During 2018, a related party forgave an outstanding balance of $21,350 and the forgiveness of related party debt was recorded in additional paid-in capital.

 

NOTE 5 – INCOME TAXES

 

On December 22, 2017, the 2018 Tax Cuts and Jobs Act (“the Tax Act”) was enacted into law including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2019, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. The Company does not have any foreign earnings and therefore, we do not anticipate the impact of a transition tax.

 

We have remeasured our U.S. deferred tax assets at a statutory income tax rate of 21%. Since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12 months, we consider the accounting of any transition tax, deferred tax re-measurements, and other items to be incomplete due to the forthcoming guidance and our ongoing analysis of final year-end data and tax

 

positions. We expect to complete our analysis within the measurement period in accordance with SAB 118, no later than 2019.


16


KREIDO BIOFUELS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018


 

The cumulative tax effect at the expected rate of 21% as of December 31, 2019 and 35% as of December 31, 2018 of significant items comprising our net deferred tax amount is as follows:

 

 

 

2019

2018

Net operating loss carryover

49,044,627

49,011,291

Deferred tax asset

10,299,372

10,292,371

Impact of rate changes

-

-

Less: valuation allowance

(10,299,372)

(10,292,271)

Net deferred tax asset

$                            -

$                               -

 

At December 31, 2019, the Company had net operating loss carry forwards of approximately $49,044,627 that may be offset against future taxable income. The Tax Act also changed the rules on net operating loss carry forwards. The 20-year limitation was eliminated, giving the taxpayer the ability to carry forward losses indefinitely. However, NOL carry forward arising after January 1, 2019, will now be limited to 80 percent of taxable income.

 

No tax benefit has been reported in the December 31, 2019, consolidated financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

 

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for federal income tax reporting purposes are subject to annual limitations. A change in ownership may limit net operating loss carry forwards in future years.  The last three years of tax returns are open for examination by taxing authorities.

 

NOTE 6 – RELATED PARTY TRANSACTIONS

As of December 31, 2019, the Company has a related party payable in the amount of $32,512. At the year ended December 31, 2018, the Company had a related party receivable in the amount of $12,233.

During 2019, a related party paid a total of $20,279 for professional fees and paying off outstanding note payable balances on behalf of the Company.

 

NOTE 7 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from December 31, 2019 through the date the financial statements were issued and there have been no subsequent events for which disclosure is required.


17



ITEM 9CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 

 

None.

 

ITEM 9ACONTROLS AND PROCEDURES   

 

Management’s Evaluation on Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, to allow for timely decisions regarding required disclosure.

 

As of December 31, 2019, we carried out an evaluation, under the supervision of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, we concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this quarterly report. Our board of directors has only one member. We do not have a formal audit committee.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Our control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that: 

 

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of our assets; 

 

provide reasonable assurance that the transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures are being made only with proper authorizations of management and directors; and 

 

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of company assets that could have a material effect on the financial statements. 

 

Because of inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  

Management, including our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2019. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the 2013 Internal Control Over Financial Reporting – Guidance for Smaller Public Companies. Based on our assessment and those criteria, our management concluded that our internal control over financial reporting was not effective as of December 31, 2019. 

 

 

Changes in Internal Control over Financial Reporting

 

There have been no significant changes in our internal controls over financial reporting that occurred during the year ended December 31, 2019, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

 

 

ITEM 9BOTHER INFORMATION 

 

None.

 

PART III

 

ITEM 10DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE  


18



Directors, Executive Officers, Promoters and Control Persons

 

Set forth below is the name and age of each of our directors and executive officers as of December 31, 2019, together with all positions and offices held by them, the term of office and the period during which they have served.  All directors hold office for one year or until their successors are elected or appointed at the next annual meeting of our shareholders.  Our officers are appointed by our board of directors and hold office until their resignation or removal from office. The names, ages and positions of our directors and executive officers as of December 31, 2019, are as follows:

 

  NAME

 AGE

POSITION

   APPOINTED

TERM

CHAN Kwok Wai Davy

47

Chief Executive Officer

Chief Financial Officer

Secretary

Director

September 7, 2021

 

 

 

 

 

 

 

The following is a brief account of the education and business experience during the past five years of our directors and officers, indicating their principal occupation during that period, and the name and principal business of the organization in which such occupation and employment were carried out.

 

 CHAN Kwok Wai Davy was the sole investor in Hong Kong style local restaurants in various Provinces in China. From 2009 until 2011, CHAN Kwok Wai Davy was an independent investment consultant in China. Since 2012, CHAN Kwok Wai Davy established the Evergreen Group for soliciting China enterprises or high-worth investors to invest in Hong Kong securities markets and or China business projects.

 

As our President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Principal Accounting Officer, Mr. Wong is responsible for the general direction of our business development including day-to-day management of business affairs.

 

Significant Employees

 

As of December 31, 2019, we did not have any employees who are expected to make a significant contribution to our business.

 

Family Relationships

 

There are no family relationships among directors or executive officers.  

 

Involvement in Certain Legal Proceedings

 

Mr. Wong has not been involved in any legal proceedings that are material to an evaluation of his ability or integrity.

 

None of our directors or officers has filed any bankruptcy petition.

 

None of our directors or officers has been the subject of any order, judgment, or decree permanently or temporarily enjoining him from, or otherwise limiting, them from acting as a futures commission, merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, or any other person regulated by the Commodity Futures Trading Commission, or an associated person of such, or as an investment adviser, underwriter, broker or dealer in securities or as an affiliated person, director or employee of an investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; engaging in any type of business practice; or engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws. None of our directors or officers has been permanently or temporarily enjoined, barred, suspended or otherwise limited from involvement in any type of securities or banking activities.

 

None of our directors or officers has been convicted of violating a federal or state securities or commodities law.

None of our directors or officers has been subject or a party to any sanction or order of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act, any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent.

 

Code of Ethics

 

Our Company has not adopted a Code of Ethics


19



Board of Directors

 

As of the date of this Report, we have one director on our board: Wai Lim Wong.  The director is not considered to be independent.  We plan to appoint additional independent directors to our board and committees in the future.  Our directors are reimbursed for expenses, if any, but our current director does not currently receive compensation.  Our board of directors may designate from among its members an executive committee and one or more other committees but has not done so to date.  We do not have a nominating committee or a nominating committee charter.  Further, we do not have a policy with regard to the consideration of any director candidates recommended by security holders.  To date,  no security holders have made any such recommendations.  Our directors perform all functions that would otherwise be performed by committees.  Given the present size of our board, it is not practical for us to have committees.  If we are able to grow our business and increase our operations, we intend to expand the size of our board and allocate responsibilities accordingly.

 

 

Audit Committee

 

As sole director, Mr. Wong performs the function of an audit committee and is not considered to be independent. If we find a business opportunity, we may appoint additional independent directors to our board and committees in the future. We do not have any independent board members on our audit committee who are financial experts. We do not have an audit committee financial expert, or any committee or person performing a similar function. We currently have limited working capital and revenues. Management does not believe that it would be in our best interests at this time to retain independent directors to sit on an audit committee.

 

Corporate Governance

 

As of the date of this Report, no material changes were made to the procedures by which security holders may recommend nominees to our board of directors.

 

Compliance with Section 16(a) of the Exchange Act

 

To the best of our knowledge based on the available information as of December 31, 2019, all our executive officers and directors and persons who own more than 10% of a registered class of our equity securities filed all Section 16(a) reports with the SEC in a timely manner and provided us with copies of initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our common stock and other equity securities on Forms 3, 4, 5 and amendments thereto respectively in accordance with the requirements of the Section 16(a) of the Exchange Act.

 

ITEM 11EXECUTIVE COMPENSATION 

 

The following table sets forth certain information regarding our officers, directors and employees' annual and long-term compensation for the fiscal years ended December 31, 2019 and 2018.  We do not currently have any employment related benefits, such as health or life insurance, available for our officers, directors and employees.  Our directors, officers and employees do not currently receive any long-term compensation.

 

Name and Principal Position

Fiscal Year

Salary ($)

Bonus

Options Awards

All Other Compensation

Total ($)

Wai Lim Wong

Former President and Chairman

2019

2018

$

$

0

0

0

0

0

0

0

0

0

0

 

 

 

 

 

 

 

 

 

There are no annuity, pension or retirement benefits proposed to be paid to our officers, directors or employees in the event of retirement at normal retirement date.

 

No remuneration is proposed to be paid in the future either directly or indirectly by us to any officer or director.

 

Employment Agreements

 

None

 

Compensation of Directors

 

None

 

Stock Option Grants


20



As of the date of this Report, we have not granted any stock options.  We have not adopted any equity compensation plans since our inception.

 

Compensation Committee

 

Kreido Biofuels, Inc. has not yet provided any compensation to its directors in the fiscal year ended December 31, 2019. The Company may establish certain compensation plans (e.g. options, cash for attending meetings, etc.) with respect to directors in the future. Prior to the Share Purchase, G. Reed Petersen, the sole director and officer of the Company was not receiving compensation for his services.

 

Indemnification

 

Nevada law and the Company’s Bylaws provide that the Company will indemnify, to the fullest extent permitted by applicable law, any person, and the estate and personal representative of any such person, against all liability and expense (including attorneys’ fees and costs of litigation) incurred by reason of the fact that such person is or was a director or officer of the Company or, while servicing as a director or officer of the Company, is or was serving at the request of the Company as a director, officer, partner, trustee, employee, fiduciary, or agent of, or in any similar managerial or fiduciary position of, another domestic or foreign corporation or other entity or of an employee benefit plan.

 

ITEM 12SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 

 

The following table sets forth certain information as of December 31, 2019, with respect to the beneficial ownership of our common stock by (1) each director, (2) each executive officer, (3) each significant employee, (4) our directors and officers as a group, (5) and each person known by us to own beneficially more than 5% of our common stock.  Under relevant provisions of the Exchange Act, a person is deemed to be a “beneficial owner” of a security if he or she has, or shares, the power to vote or direct the voting of the security or the power to dispose of or direct the disposition of the security.  A person is also deemed to be a beneficial owner of any securities of which that person has the right to acquire beneficial ownership within 60 days.  More than one person may be deemed to be a beneficial owner of the same securities. The percentage ownership of each stockholder is calculated based on 1,956,452 outstanding shares of our common stock as of December 31, 2019.

 

 

 

Class of Stock

Name of Beneficial Owner (1)

Number of Common Shares

Percentage of Class

Common shares

Wai Lim Wong, Former CFO, CEO, President, Director

0

0%

Common shares

Chu Ju Dou

554,855

28.36%

Common shares

Chao Zhang

214,386

10.96%

 

Officers and Directors as a Group

769,241

39.32%

 

Changes in Control

As of the date of this Report, our management is unaware of any existing or anticipated contract or arrangement, the operation of which may, at a subsequent date, result in a changes in our control.

 

Securities Authorized for Issuance Under Equity Compensation Plans

We have not adopted any equity compensation plans since our inception.

 

ITEM 13CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 

 

Transactions with Related Persons

 

None

 

Director Independence

 

As of the date of this Report, we have one director on our board, Wai Lim Wong, who is not considered to be independent.  We plan to appoint additional independent directors to our board and committees in the future.  We do not have any independent board members or an audit committee considered to be financial experts.


21



ITEM 14PRINCIPAL ACCOUNTANT FEES AND SERVICES 

 

Audit Fees

The aggregate fees billed to us by our auditor for services rendered during the fiscal years ended December 31, 2019 and 2018, are set forth in the table below:

 

Fee Category

Fiscal year ended

December 31, 2019

Fiscal year ended

December 31, 2018

 

 

 

Audit fees (1)

$

$

Audit-related fees (2)

0

0

Tax fees (3)

0

0

All other fees (4)

0

0

Total fees

$

$

 

(1)Audit fees consist of fees incurred for professional services rendered for the audit of our financial statements, for reviews of our interim financial statements included in our quarterly reports on Form 10-Q and for services that are normally provided in connection with statutory or regulatory filings or engagements. 

(2)Audit-related fees consist of fees billed for professional services that are reasonably related to the performance of the audit or review of our financial statements, but are not reported under “Audit fees.”  

(3)Tax fees consist of fees billed for professional services relating to tax compliance, tax planning, and tax advice. 

(4)All other fees consist of fees billed for all other services. 

Audit Committee’s Pre-Approval Practice

Our board of directors performs the function of an audit committee.  Section 10A(i) of the Exchange Act prohibits our auditors from performing audit services for us as well as any services not considered to be audit services unless such services are pre-approved by our audit committee or, in cases where no such committee exists, by our board of directors (in lieu of an audit committee) or unless the services meet certain minimum standards.

 

 

 

 

 

 

PART IV

 

ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 

 

Exhibits

 

The following exhibits are included as part of this Report:

 

Exhibit No.

 

Description

 

 

 

3.1

 

Certificate of Incorporation and Bylaws(1)

 

 

 

31.1

 

Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Executive and Financial Officer

 

 

 

32.1

 

Rule 1350 Certification of Principal Executive and Financial Officer

 

 

 

101.INS (2)

 

XBRL Instance

 

 

 

101.SCH (2)

 

XBRL Taxonomy Extension Schema

 

 

 

101.CAL (2)

 

XBRL Taxonomy Extension Calculation

 

 

 

101.DEF (2)

 

XBRL Taxonomy Extension Definition

 

 

 

101.LAB (2)

 

XBRL Taxonomy Extension Labels

 

 

 


22



101.PRE (2)

 

XBRL Taxonomy Extension Presentation

 

(1)Filed with the SEC on November 3, 2006, as an exhibit, numbered as indicated above, to the Current Report on Form 8-K, which exhibit is incorporated herein by reference.  

(2)XBRL Information is furnished and not filed or a part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act is deemed not filed for purposes of Section 18 of the Exchange Act and otherwise is not subject to liability under these sections. 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date:  09/24/21

 

KREIDO BIOFUELS, INC.

 

 

By /s/ CHAN Kwok Wai Davy

Name: CHAN Kwok Wai Davy

Title: President, Chief Executive Officer, Chief Financial Officer, Secretary, Principal Accounting Officer, Director

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

 

/s/ CHAN Kwok Wai DavyDated:09/24/2021 

CHAN Kwok Wai Davy

President, CEO, CFO, Secretary, Treasurer

Principal Accounting Officer, Director


23

Kreido Biofuels (PK) (USOTC:KRBF)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Kreido Biofuels (PK) Charts.
Kreido Biofuels (PK) (USOTC:KRBF)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Kreido Biofuels (PK) Charts.